Key Drivers
- Leverage Risk
- Dividend Strain
- Cash Flow Volatility
AIAI Summary
ALX should be viewed less as a dependable income REIT and more as a leveraged capital-allocation story with shrinking cash-flow depth: the Rego Park sale may buy flexibility if proceeds go to debt reduction, but with Q1 2026 FFO, free cash flow, and dividend coverage all weakening, the stock looks vulnerable until management proves it can preserve earnings power while de-levering.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Leverage Risk
- •Dividend Strain
- •Cash Flow Volatility
ALX remains profitable, but its highly leveraged balance sheet, weak quarterly cash flow, and unsustainably high dividend payout make the current 41.0x earnings valuation look stretched.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Resistance overhead
ALX is in a short-term pullback with lower highs/lows, holding near $226.85–$227 support but needing a reclaim of $235–$241 to turn the near-term trend positive.
Fell from $247.54 to $229.88 over the last month, signaling weakening momentum
Sentiment & News
Key News Insights:
- •Dividend support
- •FFO miss
- •Clinical progress
Alexander's showed dividend support but weaker first-quarter FFO and share pressure, while ALX Oncology's latest headlines highlighted encouraging evorpacept clinical progress and pipeline momentum.
Overall, the news is mildly negative for Alexander's due to the earnings miss, while it is constructive for ALX Oncology as clinical updates may support sentiment
Similar Companies in Real Estate
Other companies in the same sector with AI ratings